Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
196.19
+3.38 (1.75%)
At close: Jun 26, 2026, 4:00 PM EDT
194.74
-1.45 (-0.74%)
After-hours: Jun 26, 2026, 7:54 PM EDT

Company Description

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.

The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.

The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands.

The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.

Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Danaher Corporation
Danaher logo
Country United States
Founded 1969
Industry Diagnostics & Research
Sector Healthcare
Employees 60,000
CEO Rainer Blair

Contact Details

Address:
2200 Pennsylvania Avenue N.W., Suite 800W
Washington, District of Columbia 20037-1701
United States
Phone 202 828 0850
Website danaher.com

Stock Details

Ticker Symbol DHR
Exchange NYSE
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000313616
CUSIP Number 235851102
ISIN Number US2358511028
Employer ID 59-1995548
SIC Code 3823

Key Executives

Name Position
Christopher Paul Riley Executive Vice President of Biotechnology Group and Chief Executive Officer of Cytiva
Rainer M. Blair President, Chief Executive Officer and Director
Steven M. Rales Co-Founder and Chairman
Mitchell P. Rales Co-Founder and Director
Dr. Jose-Carlos Gutierrez-Ramos Ph.D. Senior Vice President and Chief Science Officer
Matthew R. McGrew Executive Vice President
Julie Sawyer Montgomery Executive Vice President of Diagnostics Platform
Christopher M. Bouda Vice President and Chief Accounting Officer
Dr. Martin Stumpe Ph.D. Chief Technology and AI Officer
Rachel Marie Vatnsdal Olson Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Jun 16, 2026 11-K Annual report of employee stock purchase, savings and similar plans
Jun 9, 2026 S-8 Securities to be offered to employees in employee benefit plans
Jun 9, 2026 S-8 Securities to be offered to employees in employee benefit plans
Jun 3, 2026 8-K Current Report
May 12, 2026 SD Form - SD
May 7, 2026 8-K Current Report
May 1, 2026 144 Filing
Apr 30, 2026 CERT Certification by an exchange approving securities for listing
Apr 29, 2026 SCHEDULE 13G Filing
Apr 29, 2026 8-A12B Registration of securities